Incyte (INCY) EBIT Growth (3y) (2013 - 2026)

Incyte (INCY) EBIT Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 16.96%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 38.78%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 13.47%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -12.10%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 69.02%
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Incyte 23.33 Bn 19.32 Bn 1.17 Bn 129.93%

Historic Data

Download Data
DateValue
Mar 31, 2026 129.93%
Dec 31, 2025 68.59%
Sep 30, 2025 47.44%
Jun 30, 2025 27.74%
Mar 31, 2025 20.75%
Dec 31, 2024 39.64%
Sep 30, 2024 -14.70%
Jun 30, 2024 -75.39%
Mar 31, 2024 -2.38%
Dec 31, 2023 4.47%
Sep 30, 2023 242.88%
Jun 30, 2023 -5.66%
Mar 31, 2023 26.77%
Dec 31, 2022 -9.64%
Sep 30, 2022 1.00%
Jun 30, 2022 37.16%
Mar 31, 2022 16.31%
Dec 31, 2021 10.54%
Sep 30, 2021 96.31%
Jun 30, 2021 19.16%